Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01068327 · ClinicalTrials.gov registry record · Phase 1
Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer
A Phase 1 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT01068327 is a Phase 1 study that has completed, run by University of Nebraska. The registered enrollment target is 46 participants.
The verdict
NCT01068327, a Phase 1 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of stereotactic radiation therapy and nelfinavir mesylate when given together with gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Drugs, such as nelfinavir mesylate, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as gemcitabine hydrochloride, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving stereotactic radiation therapy and nelfinavir mesylate together with combination chemotherapy may kill more tumor cells.
Interventions
- RADIATION stereotactic body radiation therapy
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG gemcitabine hydrochloride
- DRUG nelfinavir mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2007-11-05 |
| Est. Completion | 2015-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01068327
The ClinicalTrials.gov registry entry for NCT01068327 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which stereotactic body radiation therapy is the first listed.
NCT01068327 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01068327 about?
NCT01068327 is a clinical study titled "Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer". This phase I trial is studying the side effects and best dose of stereotactic radiation therapy and nelfinavir mesylate when given together with gemcitabine hydrochloride, leucovorin calcium, and fluorouracil in treating patients with locally advanced pancreatic cancer. Stereotactic radiation therap...
What is the current status of trial NCT01068327?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2007-11-05. Estimated completion is 2015-02-01.
What interventions are being tested in trial NCT01068327?
The interventions under investigation include: stereotactic body radiation therapy (RADIATION), fluorouracil (DRUG), leucovorin calcium (DRUG), gemcitabine hydrochloride (DRUG), nelfinavir mesylate (DRUG).
Who is sponsoring clinical trial NCT01068327?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.